Prehypertension remains an important public health challenge all over the world and appropriate treatments should be adopted to prehypertensive group in different degree effectively. This review aimed to assess the prevalence of Prehypertension and provide effective evidence of the benefits of treating prehypertensive patients. The reasonable evaluation and appropriate intervention of prehypertensive remain need further study. 1. Introduction Prehypertension was defined as a systolic blood pressure of 120–139？mmHg and/or a diastolic blood pressure of 80–89？mmHg. The concept of prehypertension was introduced as the new guideline for the management of blood pressure by the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JnC-7) [1]. The objectives of defining this classification of blood pressure were to draw the clinical and public healthy attention on the prevention of people in this range. Prehypertension is a precursor of clinical hypertension and is closely related with the increased incidence of cardiovascular disease [2–4]. Patients with Prehypertension (120–139/80–89？mmHg) have an increased risk of cardiovascular morbidity and mortality compared with patients who have normal blood pressure (<120/80？mmHg). This paper aimed to assess the prevalence of Prehypertension and provide effective evidence of the benefits of treating prehypertensive patients in community. 2. Epidemiology 2.1. High Prevalence of Prehypertension The National Health and Nutrition Examination Survey (NHANES) 1999-2000 reported that the overall prevalence of prehypertension was 31% all over the world, which was higher in men than in women [5]. A statistical analysis of disease-free adult NHANES participants which was conducted from 1999 to 2006 found that the overall prevalence of PreHTN in disease-free adults was 36.3% [6]. The ATTICA study which included 1514 men and 1528 women found that the prehypertensive population was 39% (43% in men and 35% in women) [7]. The prevalence of prehypertension in India was found more than 45% (of the 2,007 people studied, 47.4% had Prehypertension and 34.7% had hypertension. Prehypertension was found in 46.6% of the men and 49.8% of the women). The data from Korean Nation Health and Nutrition Survey 2001 reported that the estimated age-adjusted prevalence of hypertension and prehypertension was 22.9% (26.9% in men, 20.5% in women) and 31.6% (41.9% in men, 25.9% in women [8]). The Jichi Medical School Cohort Study showed that the prevalence of prehypertension was 34.8%
References
[1]
A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003.
[2]
R. S. Vasan, M. G. Larson, E. P. Leip, W. B. Kannel, and D. Levy, “Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study,” The Lancet, vol. 358, no. 9294, pp. 1682–1686, 2001.
[3]
H. A. Liszka, A. G. Mainous, D. E. King, C. J. Everett, and B. M. Egan, “Prehypertension and cardiovascular morbidity,” Annals of Family Medicine, vol. 3, no. 4, pp. 294–299, 2005.
[4]
K. C. Ferdinand and R. S. Pacini, “New evidence confirms risks associated with prehypertension and benefits of therapeutic lifestyle changes in management,” Journal of the Cardiometabolic Syndrome, vol. 2, no. 4, pp. 302–304, 2007.
[5]
Y. Wang and Q. J. Wang, “The prevalence of prehypertension and hypertension among US Adults According to the New Joint National Committee Guidelines: new challenges of the old problem,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2126–2134, 2004.
[6]
A. K. Gupta, M. McGlone, F. L. Greenway, and W. D. Johnson, “Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile,” Hypertension Research, vol. 33, no. 9, pp. 905–910, 2010.
[7]
C. Chrysohoou, C. Pitsavos, D. B. Panagiotakos, J. Skoumas, and C. Stefanadis, “Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study,” American Journal of Hypertension, vol. 17, no. 7, pp. 568–573, 2004.
[8]
K. M. Choi, H. S. Park, J. H. Han et al., “Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001,” Journal of Hypertension, vol. 24, no. 8, pp. 1515–1521, 2006.
[9]
Y. Ishikawa, J. Ishikawa, S. Ishikawa et al., “Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School cohort study,” Hypertension Research, vol. 31, no. 7, pp. 1323–1330, 2008.
[10]
J. W. Sit, L. Sijian, E. M. Wong et al., “Prevalence and risk factors associated with prehypertension: identification of foci for primary prevention of hypertension,” Journal of Cardiovascular Nursing, vol. 25, no. 6, pp. 461–469, 2010.
[11]
J. Yang, F. Lu, C. Zhang et al., “Prevalence of prehypertension and hypertension in a Chinese rural area from 1991 to 2007,” Hypertension Research, vol. 33, no. 4, pp. 331–337, 2010.
[12]
K. J. Greenland, J. B. Croft, and G. A. Mensah, “Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2113–2118, 2004.
[13]
A. R. Mainous, C. J. Everett, H. Liszka, D. E. King, and B. M. Egan, “Prehypertension and mortality in a nationally representative cohort,” American Journal of Cardiology, vol. 94, no. 12, pp. 1496–1500, 2004.
[14]
S. L. Wu, Z. Q. Zhang, S. B. Song, et al., “Prevalence of prehypertension and associated cardiovascular risk: two years follow up results,” Chinese Journal of Epidemiology, vol. 38, no. 5, pp. 415–419, 2010.
[15]
S. A. Isezuo, A. A. Sabir, A. E. Ohwovorilole, and O. A. Fasanmade, “Prevalence, associated factors and relationship between prehypertension and hypertension: a study of two ethnic African populations in Northern Nigeria,” Journal of Human Hypertension, vol. 25, pp. 224–230, 2011.
[16]
A. Cordero, M. Laclaustra, M. León et al., “Prehypertension is associated with insulin resistance state and not with an initial renal function impairment: a Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy,” American Journal of Hypertension, vol. 19, no. 2, pp. 189–196, 2006.
[17]
Y. Zhang, E. T. Lee, R. B. Devereux et al., “Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the strong heart study,” Hypertension, vol. 47, no. 3, pp. 410–414, 2006.
[18]
B. J. Kim, H. J. Lee, K. C. Sung et al., “Comparison of microalbuminuria in 2 blood pressure categories of prehypertensive subjects,” Circulation Journal, vol. 71, no. 8, pp. 1283–1287, 2007.
[19]
C. Chrysohoou, C. Pitsavos, D. B. Panagiotakos, J. Skoumas, and C. Stefanadis, “Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study,” American Journal of Hypertension, vol. 17, no. 7, pp. 568–573, 2004.
[20]
T. Ninomiya, M. Kubo, Y. Doi et al., “Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama study,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2135–2142, 2007.
[21]
B. Marilyn, W. Lawrence, B. Richard, et al., “Association of prehypertension by joint national committee 7 criteria with left ventrieulur structure and function: the strong heart study,” Journal of the American College of Cardiology, vol. 17, no. 3, pp. 1142–1183, 2004.
[22]
A. V. Kshirsagar, M. Carpenter, H. Bang, S. B. Wyatt, and R. E. Colindres, “Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease,” American Journal of Medicine, vol. 119, no. 2, pp. 133–141, 2006.
[23]
A. I. Qureshi, M. F. Suri, J. F. Kirmani, A. A. Divani, and Y. Mohammad, “Is prehypertension a risk factor for cardiovascular diseases?” Stroke, vol. 36, no. 9, pp. 1859–1863, 2005.
[24]
S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies,” The Lancet, vol. 360, no. 9349, pp. 1903–1913, 2002.
[25]
R. S. Vasan, M. G. Larson, E. P. Leip, W. B. Kannel, and D. Levy, “Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study,” The Lancet, vol. 358, no. 9294, pp. 1682–1686, 2001.
[26]
T. Dorjgochoo, X. O. Shu, X. Zhang et al., “Relation of blood pressure components and categories and all-cause, stroke and coronary heart disease mortality in urban Chinese women: a population-based prospective study,” Journal of Hypertension, vol. 27, no. 3, pp. 468–475, 2009.
[27]
G. Mancia, G. De Backer, A. Dominiczak et al., “2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension,” Journal of Hypertension, vol. 25, no. 9, pp. 1751–1762, 2007.
[28]
N. M. Karanja, E. Obarzanek, P. H. Lin et al., “Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension trial,” Journal of the American Dietetic Association, vol. 99, supplement 8, pp. S19–S27, 1999.
[29]
F. M. Sacks, L. P. Svetkey, W. M. Vollmer et al., “Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (dash) diet,” New England Journal of Medicine, vol. 344, no. 1, pp. 3–10, 2001.
[30]
J. E. Neter, B. E. Stam, F. J. Kok, D. E. Grobbee, and J. M. Geleijnse, “Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials,” Hypertension, vol. 42, no. 5, pp. 878–884, 2003.
[31]
G. Cocco and S. Pandolfi, “Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients,” Journal of Clinical Hypertension, vol. 13, no. 1, pp. 23–29, 2011.
[32]
F. P. Costa and S. H. Machado, “Does the consumption of salt and food rich in sodium influence in the blood pressure of the infants?” Ciencia e Saude Coletiva, vol. 15, supplement 1, pp. 1383–1389, 2010.
[33]
K. Miura, N. Okuda, T. C. Turin et al., “Dietary salt intake and blood pressure in a representative Japanese population: baseline analyses of NIPPON DATA80,” Journal of Epidemiology, vol. 20, supplement 3, pp. S524–S530, 2010.
[34]
N. R. Cook, J. A. Cutler, E. Obarzanek et al., “Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP),” British Medical Journal, vol. 334, no. 7599, pp. 885–888, 2007.
[35]
G. A. Kelley and K. S. Kelley, “Progressive resistance exercise and resting blood pressure: a meta- analysis of randomized controlled trials,” Hypertension, vol. 35, no. 3, pp. 838–843, 2000.
[36]
S. P. Whelton, A. Chin, X. Xin, and J. He, “Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials,” Annals of Internal Medicine, vol. 136, no. 7, pp. 493–503, 2002.
[37]
I. B. Puddey and L. J. Beilin, “Alcohol is bad for blood pressure,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 9, pp. 847–852, 2006.
[38]
P. J. Elmer, E. Obarzanek, W. M. Vollmer et al., “Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-Month results of a randomized trial,” Annals of Internal Medicine, vol. 144, no. 7, pp. 485–495, 2006.
[39]
J. F. Martin, L. N. Martin, and J. P. Cipullo, “Pharmacologic treatment for prehypertension: to treat or not to treat?” Recent Patents on Cardiovascular Drug Discovery, vol. 4, no. 2, pp. 133–141, 2009.
[40]
S. Julius, S. D. Nesbitt, B. M. Egan et al., “Feasibility of treating prehypertension with an angiotensin-receptor blocker,” New England Journal of Medicine, vol. 354, no. 16, pp. 1685–1697, 2006.
[41]
J. A. Cadée, C. Y. Chang, C. W. Chen, C. N. Huang, S. L. Chen, and C. K. Wang, “Bovine casein hydrolysate (C12 Peptide) reduces blood pressure in prehypertensive subjects,” American Journal of Hypertension, vol. 20, no. 1, pp. 1–5, 2007.
[42]
F. D. Fuchs, “Prehypertension: the rationale for early drug therapy,” Cardiovascular Therapeutics, vol. 28, no. 6, pp. 339–343, 2010.
[43]
E. Pimenta and S. Oparil, “Prehypertension: epidemiology, consequences and treatment,” Nature Reviews Nephrology, vol. 6, no. 1, pp. 21–30, 2010.
